


### I. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### **Listing of Claims:**

Claim 1 (withdrawn): A method for enhancing the radiosensitivity of a neoplastic cell comprising contacting the neoplastic cell with a radiosensitivity increasing amount of indolocarbazole derivative having the following structure A




wherein R<sub>1</sub> is not NCH<sub>3</sub> and wherein R<sub>2</sub> and R<sub>3</sub> are not H when R<sub>1</sub> is NH.

Claim 2 (withdrawn): The method of claim 1, wherein R<sub>1</sub> is NH, O, or NOH.

Claim 3 (withdrawn): The method of claim 1, wherein R<sub>2</sub> and R<sub>3</sub> are Cl or H.

Claim 4 (withdrawn): The method of claim 1, wherein the amount of indolocarbazole derivative is at a non-cytotoxic level.

Claim 5 (withdrawn): A method for enhancing the radiosensitivity of a neoplastic cell comprising contacting the neoplastic cell with a radiosensitivity increasing amount of a composition comprising an indolocarbazole derivative having the following structure A



wherein R<sub>1</sub> is not NCH<sub>3</sub> and wherein R<sub>2</sub> and R<sub>3</sub> are not H when R<sub>1</sub> is NH.

Claim 6 (withdrawn): The method of claim 5, wherein R<sub>1</sub> is NH, O, or NOH.

Claim 7 (withdrawn): The method of claim 5, wherein R<sub>2</sub> and R<sub>3</sub> are Cl or H.


Claim 8 (withdrawn): The method of claim 5, wherein the composition further comprises a pharmaceutically acceptable carrier.

Claim 9 (withdrawn): The method of claim 5, wherein the amount of composition is at a non-cytotoxic level.

Claim 10 (withdrawn) The method of claim 1, wherein the neoplastic cell is solid tumor cell or cancer cell.

Claim 11 (withdrawn): The method of claim 1, wherein the neoplastic cell is selected from the group consisting of prostate cancer cell, bone cancer cell, colon cancer cell, lymphoma cancer cell, and brain cancer cell.

Claim 12 (withdrawn): A method for treating a neoplastic cell comprising contacting the neoplastic cell with a radiosensitivity increasing amount of indolocarbazole derivative having the following structure A



wherein R<sub>1</sub> is not NCH<sub>3</sub> and wherein R<sub>2</sub> and R<sub>3</sub> are not H when R<sub>1</sub> is NH; and

contacting the neoplastic cell with radiation or radiation in combination with an anti-neoplastic chemotherapeutic agent.


Claim 13 (withdrawn): The method of claim 12, wherein R<sub>1</sub> is NH, O, or NOH.

Claim 14 (withdrawn): The method of claim 12, wherein R<sub>2</sub> and R<sub>3</sub> are Cl or H.

Claim 15 (withdrawn): The method of claim 12, wherein the neoplastic cell is contacted with the indolocarbazole derivative before being contacted with radiation or radiation in combination with an anti-neoplastic chemotherapeutic agent.

Claim 16 (withdrawn): The method of claim 12, wherein the amount of indolocarbazole derivative is at a non-cytotoxic level.

Claim 17 (withdrawn): A method for treating a neoplastic cell comprising contacting the neoplastic cell with a radiosensitivity increasing amount of a composition comprising an indolocarbazole derivative having the following structure A



wherein R<sub>1</sub> is not NCH<sub>3</sub> and wherein R<sub>2</sub> and R<sub>3</sub> are not H when R<sub>1</sub> is NH; and contacting the neoplastic cell with radiation or radiation in combination with an anti-neoplastic chemotherapeutic agent.

Claim 18 (withdrawn): The method of claim 17, wherein R<sub>1</sub> is NH, O, or NOH.

Claim 19 (withdrawn): The method of claim 17, wherein R<sub>2</sub> and R<sub>3</sub> are Cl or H.


Claim 20 (withdrawn): The method of claim 17, wherein the composition further comprises a pharmaceutically acceptable carrier.

Claim 21 (withdrawn): The method of claim 17, wherein the amount of composition is at a non-cytotoxic level.

Claim 22 (withdrawn): The method of claim 17, wherein the neoplastic cell is contacted with the composition before being contacted with radiation or radiation in combination with an anti-neoplastic chemotherapeutic agent.

Claims 23-41 (canceled)

Claim 42 (new). A method for enhancing the effect of radiation comprising administering to a subject in need of such treatment a radiosensitivity increasing amount of an indolocarbazole derivative having the following structure A



wherein R<sub>1</sub> is not NCH<sub>3</sub> and wherein R<sub>2</sub> and R<sub>3</sub> are not H when R<sub>1</sub> is NH; and wherein the subject is treated with radiation and the amount of indolocarbazole derivative is at a non-cytotoxic level.

Claim 43 (new). The method of claim 42, wherein R<sub>1</sub> is NH, O, or NOH.

Claim 44 (new). The method of claim 42, wherein R<sub>2</sub> and R<sub>3</sub> are Cl or H.

Claim 45 (new). The method of claim 42, wherein the indolocarbazole derivative is administered before the subject is treated with radiation.

Claim 46 (new). The method of claim 42, wherein the indolocarbazole derivative is administered while the subject is treated with radiation.

Claim 47 (new). The method of claim 42, wherein the subject is treated with radiation and an anti-neoplastic chemotherapeutic agent.

Claim 48 (new). The method of claim 42, wherein the indolocarbazole derivative is administered in a pharmaceutical composition.